New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
16:03 EDTKBIOKaloBios presents clinical results from KB002 Phase 1/2 study
KaloBios Pharmaceuticals presented data from its Phase 1/2 study in persistent asthma for KB002, precursor chimeric anti-GM-CSF monoclonal antibody to KB003, at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Austin, Texas. The findings demonstrated preliminary safety, tolerability, and signs of activity of anti- GM-CSF antibodies in asthma and support continued development of the company's Humaneered KB003 anti-GM-CSF monoclonal antibody in severe asthma. KB003 is currently in a Phase 2 trial in severe asthma patients inadequately controlled by corticosteroids. "These initial clinical results with KB002 in asthma are highly encouraging. KB002 was well-tolerated, with no significant adverse events in the study population. When KB002 was added to patients' standard of care treatment, the study also showed a reduction in airway inflammation and improvements in FEV1. Moreover, asthmatics with reversible FEV1 at baseline showed greater FEV1 responses than non-reversible patients. As a result, we are targeting this patient population in our ongoing Phase 2 KB003 study," said chief medical officer Nestor Molfino.
News For KBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 25, 2015
13:15 EDTKBIOKaloBios CEO Shkreli says Turing can IPO anytime with any bank
Subscribe for More Information
13:14 EDTKBIOKaloBios CEO says may announce acquisition by year end
Subscribe for More Information
13:12 EDTKBIOKaloBios CEO says company wouldn't return calls before investment
Subscribe for More Information
13:09 EDTKBIOKaloBios CEO reiterates 60% of Daraprim is given away for $1
Subscribe for More Information
12:26 EDTKBIOMartin Shkreli reports 70.1% stake in KaloBios
On November 9, KaloBios filed with the SEC, disclosing that on November 5 KaloBios' board approved a restructuring plan involving reductions in headcount as part of a plan to reduce operating costs. On November, 13, KaloBios issued a press release stating that it had engaged The Brenner Group in connection with a plan to wind-down operations. In response to the filing and the press release, Martin Shkreli began acquiring the common stock in the open market with the intent to gain control of KaloBios, influence management of KaloBios, replace the members of the board, prevent the commencement of any bankruptcy proceedings or proceedings for the liquidation, dissolution or wind down of the company and maximize stockholder value. Martin Shkreli acquired a majority of the shares of common stock on November 17. On November 18, Martin Shkreli made a proposal to KaloBios regarding financing options, continuing operations of KaloBios and a change in KaloBios' management and composition of the board. On November 19, KaloBios appointed Shkreli to the position of CEO and chairman of the board and Moradi, Biestek and Tony Chase as members of the board, filling vacancies created by the resignation of all former directors of KaloBios in connection with these developments. On November 22, KaloBios appointed Tom Fernandez and Michael Harrison as members of the board. Martin Shkreli may, from time to time, acquire additional shares of common stock and/or other equity, debt, notes, instruments or other securities and/or derivative securities relating thereto of KaloBios in the open market or otherwise. They reserve the right to dispose of any or all of their shares of common stock in the open market or otherwise, at any time and from time to time, and to engage in any hedging or similar transactions with respect to the securities.
10:25 EDTKBIOKaloBios Chairman & CEO Martin Shkreli to discuss company
Chairman & CEO Martin Shkreli is scheduled to appear on Bloomberg TV to discuss the company on November 25 at 1 pm.
November 24, 2015
12:59 EDTKBIOGEO Investing says Aeterna Zentaris rally 'totally unwarranted'
GEO Investing tweeted, "We believe $AEZS pump is totally unwarranted and that stock will quickly follow if $KBIO sells off."
12:41 EDTKBIOExpert sees KaloBios dropping up to 50% next week, NY Post reports
Short-sales expert Timothy Sykes expects shares of KaloBios to drop up to 50% by early next week, New York Post reports. "When bio-techs are left for dead, they're really dead," Sykes told the news paper. The stock is up over 3,600% in the past five days after Martin Shkreli and a group of investors acquired 70% of the company. KaloBios is down 14% to $33.81 in midday trading. Reference Link
11:27 EDTKBIOKaloBios CEO Shkreli discloses 5,000 share purchase
New KaloBios CEO Martin Shkreli disclosed the purchase of 5,000 shares at $38.15. The shares were purchased today. Shkreli owns over 2M shares of the company. KaloBios is trading down $2.96 to $36.54 in morning trading.
09:40 EDTKBIOKaloBios discloses receipt of letter of non-compliance from Nasdaq
Subscribe for More Information
November 23, 2015
15:01 EDTKBIOKaloBios CEO Martin Shkreli bought 5,000 shares of KaloBios common stock
Subscribe for More Information
November 20, 2015
11:52 EDTKBIOMartin Shkreli says shorting Vital Therapies
Subscribe for More Information
09:58 EDTKBIOKaloBios trading resumes, shares up $8.68 to $19.08
Subscribe for More Information
09:53 EDTKBIOKaloBios halted for volatility after jumping 75% to $18.25
Subscribe for More Information
05:33 EDTKBIOKaloBios appoints Martin Shkreli as CEO
Subscribe for More Information
November 19, 2015
15:14 EDTKBIOKaloBios KB003 product could receive FDA orphan stauts, Forbes says
Subscribe for More Information
November 18, 2015
19:37 EDTKBIOKaloBios confirms communications with majority shareholder group
KaloBios Pharmaceuticals announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Shkreli regarding possible direction for the company to continue in operation. Shkreli is the founder and CEO of Turing Pharmaceuticals, a privately held biopharmaceutical company. "We have received communications from Mr. Shkreli informing us of his group's ownership position, and a proposal to continue the company's operations," said Ronald Martell, executive chairman of KaloBios. "Our board of directors is prepared to entertain any constructive proposal, which we will act upon promptly. Addressing short-term cash needs is our first priority, and we continue to be open to further dialogue." KaloBios had previously announced that it would undertake a wind-down of the business.
19:15 EDTKBIOOn The Fly: After Hours Movers
UP AFTER EARNINGS: Keurig Green Mountain (GMCR), up 16.3%... (CRM), up 5.2%... SINA (SINA), up 2.3%... NetApp (NTAP), up marginally. ALSO HIGHER: KaloBios (KBIO), up 721.3% after the disclosure of purchases by Martin Shkreli and Anthion Partners... Vitae Pharmaceuticals (VTAE), up 23.3% after reporting top-line results from its Phase 1 trial of VTP-43742... DOWN AFTER EARNINGS: Semtech (SMTC), down 8.5% after reporting quarterly results. ALSO LOWER: Sunedison (SUNE), down 10.8% after Reuters reports that Blackstone is not interested in SunEdison investment.
19:04 EDTKBIOAnthion Partners acquires 714K shares of KaloBios
Subscribe for More Information
16:57 EDTKBIOKaloBios jumps after Martin Shkreli buys shares
Shares of KaloBios are up over 400% after Martin Shkreli, the founder of Turing Pharmaceuticals, disclosed in a filing the purchase of 1.2M shares of KaloBios for an average price of $1.35 on November 16 and 17. Shares of KaloBios are up over 400% to $10.82 in after-hours trading.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use